A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo.


To theEditor:Vitiligo is anautoimmunedisease caused by autoreactive CD8 T lymphocytes that target melanocytes, and interferon-induced CXCL10 plays an important role. Simvastatin inhibits interferonsignaling by blocking activation of STAT1 and prevented and reversed disease in our mouse model. A case report described a patient with vitiligo who… (More)
DOI: 10.1016/j.jaad.2016.06.015


1 Figure or Table